Global Pharmaceutical News

Exclusive: Suspected fake Ozempic linked to three US cases of hypoglycemia

The FDA has approved the therapy based on data from the Phase III PROPEL pivotal study.

The latest development is based on data from Phase III ADVANCE and PROGRESS clinical trials.

Fabre-Kramer gains FDA approval for major depressive disorder therapy – www.quantung.com – Quantung Pharmaceutical export

Biomass will be used to meet particularly high energy demands, according to the German government's so-called "Easter Package", which aims t

UK MHRA approves AbbVie’s migraine prevention drug Aquipta. [Quantung Pharma – Quantung.com]

European PFAS ban would burden drug companies and packagers. [Quantung Pharma – Quantung.com]

Germany’s environment and agriculture ministries are reportedly working on restrictions for biofuel production so more grain can be used as

Pharma industry: Proposed ‘forever chemicals’ ban would stifle innovation, access to drugs

The European Commission and international health agencies are closely monitoring a growing incidence of avian influenza in mammals.

EU chemical and pharmaceutical trade: robust growth. [Quantung Pharma – Quantung.com]

Biden administration to provide free Covid vaccines to uninsured Americans this fall through end of 2024

The health area has never been as focused on data as it is today. From the control of expenses to the detection of fraud and the coordinatio

UnitedHealth stock jumps after earnings top estimates despite rising medical costs

A Degree in Health Science Could Be Just What the Doctor Ordered

The FDA has placed a clinical hold on Hemogenyx Pharmaceuticals’ investigational HEMO-CAR-T, which is being trialed for the treatment of acu

Amid declining demand for COVID-19 vaccines, embattled biotech Novavax is revising its advanced purchase contract with Canada’s department o

Friday, BrainStorm Cell Therapeutics posted positive Phase III data for its amyotrophic lateral sclerosis candidate NurOwn, showing that the

angioedema patients treated with Intellia’s NTLA-2002—an in vivo CRISPR-Cas9 therapy— had an average 95% reduction in the sudden, debilitati

The therapy becomes an option for moderate-to-severe plaque psoriasis in certain adults